Literature DB >> 770048

Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.

W S Dalton, R Martz, L Lemberger, B E Rodda, R B Forney.   

Abstract

Experiments investigating the possible interaction of tetrahydrocannabinol (THC) and cannabidiol (CBD), two major components of marihuana, were conducted under controlled laboratory conditions in a double-blind manner. In one study, 15 male volunteers were given placebo or 25 mug/kg of THC together with either placebo or 150 mug/kg of CBD by inhalation of the smoke of a single cigarette. All four treatments were assigned to each subject according to a series of Latin-square designs. CBD significantly attenuated the subjective euphoria of THC. Psychomotor impairment due to THC was not significantly altered by the simultaneous administration of CBD, but a trend indicating a decrease in THC-like effects was observed after the combination. When administered alone CBD was inactive for all the parameters measured. In a second study, 8 male subjects were given CBD (0 or 150 mug/kg) by smoke inhalation 30 min before THC (0 or 25 mug/kg) in a second cigarette. In contrast to the simultaneous administration of both drugs, CBD pretreatment did not alter the effects of THC on the parameters observed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 770048     DOI: 10.1002/cpt1976193300

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  35 in total

1.  Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Authors:  Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-11-15       Impact factor: 8.327

2.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Authors:  Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-12-14       Impact factor: 4.492

3.  Subjective and physiological effects after controlled Sativex and oral THC administration.

Authors:  E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 4.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 5.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

6.  Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Authors:  Nicholas Z Greene; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Psychopharmacology (Berl)       Date:  2018-09-20       Impact factor: 4.530

7.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

Review 8.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

Review 9.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

10.  A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

Authors:  Aimee L McRae-Clark; Rickey E Carter; Therese K Killeen; Matthew J Carpenter; Amy E Wahlquist; Stacey A Simpson; Kathleen T Brady
Journal:  Drug Alcohol Depend       Date:  2009-08-21       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.